Aurinia Pharmaceuticals Inc.
AUPH
$15.19
$0.281.88%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 445.14% | 220.43% | 163.69% | 107.37% | 70.78% |
| Total Depreciation and Amortization | -0.44% | -2.14% | 23.31% | 66.95% | 182.38% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -46.52% | -28.03% | -53.41% | -64.32% | 12.22% |
| Change in Net Operating Assets | 200.17% | -8,325.77% | -181.32% | 197.15% | -65.36% |
| Cash from Operations | 320.15% | 5,488.60% | 415.30% | 232.66% | 176.59% |
| Capital Expenditure | -54.18% | 23.35% | 25.33% | 60.86% | 45.93% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 837.81% | 410.84% | 18.27% | 760.37% | -103.12% |
| Cash from Investing | 794.92% | 402.40% | 19.21% | 685.48% | -79.35% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 18.21% | 23.94% | 6.41% | -19.59% | -345.20% |
| Issuance of Common Stock | 99.39% | 71.97% | 71.14% | 111.35% | 127.10% |
| Repurchase of Common Stock | -409.26% | -378.94% | -349.90% | -2,193.33% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -302.45% | -282.60% | -282.12% | -856.96% | -2,886.17% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 489.49% | 140.57% | 108.02% | 176.29% | 76.66% |